drugset / Trial / NCT01067144

Stanford Accelerated Recovery Trial (START)

NCT01067144 ↗

Phase 3 Terminated 422 enrolled Stanford University
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

The goal of this study is to determine whether administering Gabapentin prior to surgery affects duration of pain and opioid use post-surgery. The investigators aim to compare gabapentin to placebo in a prospective, randomized clinical trial in which patients will be followed post-surgery until pain resolves and opioid use ceases.

Timeline

Start
2010-05
Primary completion
2016-07
Completion
2016-07

Outcome

Missed primary endpoint

Stopped: “Trial met futility stopping point”

paper Perioperative gabapentin did not affect time to pain cessation (hazard ratio [HR], 1.04; 95% CI, 0.82-1.33; P = .73) in the intention-to-treat analysis. PMID 29238824 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Gabapentin Unknown 300 mg —
Comparator Lorazepam Small molecule 0.5 mg —